In the November 2012 issue of Hepatology, in the article entitled “Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection” (volume 56, pages 1651-1660; doi: 10.1002/hep.25842), by Stuart C. Gordon, Paul J. Pockros, Norah A. Terrault, Robert S. Hoop, Ami Buikema, David Nerenz, and Fayez M. Hamzeh, the following conflict of interest statements were inadvertently omitted.

Additional potential conflicts are as follows: Stuart C. Gordon, M.D., has received grant/research support from AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead Pharmaceuticals, GlaxoSmithKline, Intercept Pharmaceuticals, Merck, Roche Pharmaceuticals, and Vertex Pharmaceuticals. He is a consultant/adviser for Bristol-Myers Squibb, CVS Caremark, Gilead Pharmaceuticals, Merck, Vertex Pharmaceuticals, Data Monitoring Board, Tibotec/Janssen.